Login to Your Account

Aussie radiopharma firm Telix opens largest biotech IPO on the ASX since CSL

By Tamra Sami
Staff Writer

Wednesday, November 8, 2017

PERTH, Australia – Novartis AG's recent tender offer to acquire radiopharmaceuticals specialist Advanced Accelerator Applications SA (AAA) for $3.9 billion could bode well for Aussie radiopharma company Telix Pharmaceuticals Ltd., which announced its IPO to raise A$50 million (US$38.4 million) on the Australian Securities Exchange.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription